- Home
- MXCT vs SGMO Comparison
MXCT vs SGMO Comparison
Compare MXCT & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MXCT | SGMO |
|---|---|---|
| Founded | 1999 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.5M | 141.2M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MXCT | SGMO |
|---|---|---|
| Price | $0.75 | $0.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $7.50 | $5.75 |
| AVG Volume (30 Days) | 1.4M | ★ 6.4M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 66.89 |
| EPS | N/A | N/A |
| Revenue | ★ $38,627,000.00 | $36,567,000.00 |
| Revenue This Year | N/A | $4.79 |
| Revenue Next Year | $9.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 88.60 |
| 52 Week Low | $0.64 | $0.35 |
| 52 Week High | $3.58 | $1.06 |
Technical Indicators
Market Signals| Indicator | MXCT | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 33.37 | 48.09 |
| Support Level | $0.75 | $0.36 |
| Resistance Level | $1.79 | $0.56 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 61.11 | 26.10 |
Price Performance
Historical ComparisonAbout MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.